Beach Investment Management LLC. acquired a new stake in shares of Becton Dickinson and Co (NYSE:BDX) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 4,590 shares of the medical instruments supplier’s stock, valued at approximately $1,198,000. Becton Dickinson and makes up about 1.9% of Beach Investment Management LLC.’s portfolio, making the stock its 25th biggest position.
A number of other institutional investors have also recently bought and sold shares of BDX. Fundsmith Equity Fund L.P. bought a new stake in Becton Dickinson and during the 2nd quarter valued at approximately $894,775,000. FMR LLC boosted its position in Becton Dickinson and by 13.7% during the 2nd quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after acquiring an additional 2,049,874 shares in the last quarter. Charles Schwab Investment Advisory Inc. bought a new stake in Becton Dickinson and during the 2nd quarter valued at approximately $291,167,000. Vontobel Asset Management Inc. boosted its position in Becton Dickinson and by 823.0% during the 2nd quarter. Vontobel Asset Management Inc. now owns 1,013,953 shares of the medical instruments supplier’s stock valued at $250,205,000 after acquiring an additional 904,097 shares in the last quarter. Finally, Cornerstone Wealth Management LLC boosted its position in Becton Dickinson and by 233.6% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 647,786 shares of the medical instruments supplier’s stock valued at $3,286,000 after acquiring an additional 453,623 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have weighed in on BDX shares. KeyCorp reaffirmed a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a research report on Friday, August 3rd. Citigroup lifted their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Barclays started coverage on Becton Dickinson and in a research report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective on the stock. Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $256.14.
BDX stock opened at $237.32 on Tuesday. Becton Dickinson and Co has a 52-week low of $209.91 and a 52-week high of $265.87. The company has a market cap of $63.03 billion, a PE ratio of 25.03, a price-to-earnings-growth ratio of 1.40 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95.
ILLEGAL ACTIVITY NOTICE: “4,590 Shares in Becton Dickinson and Co (BDX) Acquired by Beach Investment Management LLC.” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/11/06/4590-shares-in-becton-dickinson-and-co-bdx-acquired-by-beach-investment-management-llc.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Further Reading: What does cost of debt say about a company’s financial health?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.